Magle Group – Rights Issue 2026
Rights Issue of approximately SEK 40 million
Strengthening financial flexibility and supporting a focused strategic transition
Magle Group AB (publ) has resolved on a rights issue of up to approximately SEK 40 million, subject to approval by the Extraordinary General Meeting on 10 April 2026.
- Subscription price: SEK 4.50 per share
- Issue size: ~SEK 40 million
- Subscription period: 15 – 29 April 2026
- Pre-commitments: ~85% through subscription undertakings and guarantee commitments
Background & Rationale
Over recent years, Magle Group has executed a growth strategy across biopolymers, CDMO services and medical technology. This expansion has strengthened the Group’s platform but also increased operational complexity and capital requirements.
In 2026, the Company has initiated a strategic reset, focusing on:
- Core, revenue-generating platforms
- Operational efficiency and margin improvement
- Disciplined capital allocation
The rights issue is intended to support this transition and create a stronger financial foundation for long-term growth.
Use of Proceeds
If fully subscribed, the rights issue will provide gross proceeds of approximately SEK 40 million.
Net proceeds are intended to be allocated as follows:
- ~50% – Strengthening the balance sheet and financial flexibility
Supporting financial flexibility following restructuring and impairments - ~50% – Working capital & operational efficiency
Focus on Magle Biopolymers and Magle Chemoswed
Summary of the Offering
- Record date: 14 April 2026
- Subscription rights:
1 share = 1 subscription right
7 rights = subscription for 3 new shares - Maximum new shares: 8,849,733
- Dilution (if not participating): up to ~30%
Shareholders who do not participate have the opportunity to sell their subscription rights.
Shares may also be subscribed for without subscription rights.
Timeline
| Event | Date |
| Extraordinary General Meeting | 10 April 2026 |
| Last day incl. rights | 10 April 2026 |
| First day excl. rights | 13 April 2026 |
| Record date | 14 April 2026 |
| Trading in subscription rights | 15 – 24 April 2026 |
| Subscription period | 15 – 29 April 2026 |
| Preliminary outcome | 30 April 2026 |
Commitments
The rights issue is covered up to approximately 85% through:
- Subscription undertakings ~SEK 24.8 million
- Subscription intentions ~SEK 4 million
- Guarantee commitment ~SEK 5.2 million
Total committed amount: ~SEK 34 million
The commitments are not secured by bank guarantees or similar arrangements.
Financing Framework
The rights issue forms part of a broader financing plan aimed at supporting the Company’s financial position during the ongoing strategic transition.
Bridge Financing
- ~SEK 16.4 million in subordinated loans
- Intended to be repaid via set-off in the rights issue
Bondholder Agreement (in principle)
- Waiver of maintenance covenant until 31 Dec 2026
- Conditional on raising ≥ SEK 100 million by 30 June 2026
Additional Capital Requirement
The Company intends to secure additional capital (~SEK 70+ million) through:
- Additional equity financing
- Potential divestments
Why Invest in Magle Group?
- Established platforms in Biopolymers and CDMO
- Stable underlying revenues (~SEK 300 million expected 2025)
- Strategic refocus towards profitability and efficiency
- Clear path to margin improvement
- Strong shareholder backing
Documents & Resources
- Press Release – Rights Issue (25 March 2026)
- Information Document (to be published ~14 April 2026)
- Company Certificate (sv Registreringsbevis)
- Articles of Association (sv Bolagsordning)
- Magle Q4 report 2026
- Magle Annual Report 2025
- Investor Presentation (link to Redeye presentations when available)
Contact
Aaron Wong
Interim CEO & CFO
Phone: +46 (0)76 664 35 79
Email: aaron.wong@maglegroup.com
Important Information
This page does not constitute an offer to acquire securities in any jurisdiction where such offer would be unlawful. Please refer to the full press release and upcoming Information Document for complete details, including risk factors and legal restrictions.
